Sagar Lonial, MD, FACP: View Bio

Sikander Ailawadhi, MD: View Bio

Amrita Krishnan, MD, FACP: View Bio

Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO: View Bio

Chris Elder, PharmD, BCOP: View Bio

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute Inc and The Society of Hematologic Oncology.  Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 3.0 contact hours and 1.8 contact hours in the area of pharmacology.

ILNA  

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. 

In the following ILNA subject areas: 
Care Continuum (OCN, CBCN, CPHON, AOCNP), Early Post-Transplant Management and Education (BMTCN), Foundations of Transplant (BMTCN), Late Post-Transplant Management and Education (BMTCN), Oncology Nursing Practice (OCN), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN), Quality of Life (BMTCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Treatment (OCN, CBCN, AOCNP, CPHON) 

Pharmacy 

Medical Learning Institute Inc designates this application-based continuing education activity for 3.0 contact hours (0.3 CEUs) of the Accreditation Council for Pharmacy Education. 

UAN: JA0007322-9999-26-006-H01-P

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 3.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

About This Activity

Medical Learning Institute Inc and The Society of Hematologic Oncology are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.

Medical Learning Institute Inc and The Society of Hematologic Oncology are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Chair/Planner/Author – Part 1

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor/Speakers’ Bureau: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda

Research Funding/Support: Bristol Myers Squibb, Janssen, Novartis, Takeda

Honoraria for educational activities: AXIS Medical Education, Scientific Education Support

Other: Stock Shares: TG Therapeutics (Board of Directors with Stock - Neurology and Autoimmune indications only)

Chair/Planner/Author – Part 2

Sikander Ailawadhi, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor/Speakers’ Bureau: Bristol Myers Squibb, BeiGene, Cellectar, GlaxoSmithKline, Janssen, Pfizer, Regeneron, Sanofi

Research Funding/Support (to institution): AbbVie, Ascentage,Bristol Myers Squibb, Cellectar, Genentech, GlaxoSmithKline, Janssen, Sanofi

Chair/Planner/Author – Part 3

Amrita Krishnan, MD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: AbbVie, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche, Sanofi

Other: Stock Shares: Arcellx, Bristol Myers Squibb

Planner/Author

Beth Faiman PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor/Speakers’ Bureau: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi

Honoraria for educational activities: MLI, PCE, PER

Planner/Author

Christopher Elder, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of: 

Consultant/Advisor/Speakers’ Bureau (all have ended): Boehringer Ingelheim, Eisai, Janssen, Mirati, Novartis, Pfizer, Pharmacosmos, Sanofi

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and the Society of Hematologic Oncology, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.  You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.